Immune Pharmaceuticals - 47 Year Dividend History | IMNPQ
Historical dividend payout and yield for Immune Pharmaceuticals (IMNPQ) since 1971. The current TTM dividend payout for Immune Pharmaceuticals (IMNPQ) as of July 25, 2018 is $0.00. The current dividend yield for Immune Pharmaceuticals as of July 25, 2018 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.000B |
$0.000B |
|
Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune's lead program, bertilimumab, is a first-in-class, human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. By blocking eotaxin-1, bertilimumab may prevent the migration and activation of eosinophils and other cells, thus blocking an important inflammatory pathway active in a variety of allergic and immune diseases. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporin, which is in late stage preclinical development for atopic dermatitis and psoriasis.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
